Shikari® (S-ATRIS) Anti-Risankizumab ELISA w/confirmation
RIS-QNS-SKY
Enzyme immunoassay for the quantitative determination of antibodies to Risankizumab (Skyrizi®) in serum and plasma with confirmation.
This kit has been especially developed for the quantitative determination of antibodies to Risankizumab in serum and plasma.
The Matriks Biotek® Antibody to risankizumab (Skyrizi®) Enzyme-Linked-ImmunoSorbentAssay (ELISA) Kit is intended for the quantitative determination of antibodies to risankizumab (Skyrizi®) in serum and plasma. It is for professional use only.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system.
Research Use Only (RUO)
For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 20 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 6,25 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Safety Data Sheet (SDS) | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Reygosa, M. C., et al. "Serum risankizumab levels are associated with biochemical remission in Crohn's disease." JOURNAL OF CROHNS & COLITIS. Vol. 20. GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS, 2026. | Download |
